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Three-dimensional neurite outgrowth rates within fi-
brin matrices that contained variable amounts of RGD
peptides were shown to depend on adhesion site density
and affinity. Bi-domain peptides with a factor XIIIa sub-
strate in one domain and a RGD sequence in the other
domain were covalently incorporated into fibrin gels
during coagulation through the action of the transglu-
taminase factor XIIIa, and the RGD-dependent effect on
neurite outgrowth was quantified, employing chick dor-
sal root ganglia cultured two- and three-dimensionally
within the modified fibrin. Two separate bi-domain pep-
tides were synthesized, one with a lower binding affinity
linear RGD domain and another with a higher binding
affinity cyclic RGD domain. Both peptides were cross-
linked into fibrin gels at concentrations up to 8.2 mol of
peptide/mol of fibrinogen, and their effect on neurite
outgrowth was measured. Both two- and three-dimen-
sional neurite outgrowth demonstrated a bi-phasic de-
pendence on RGD concentration for both the linear and
cyclic peptide, with intermediate adhesion site densities
yielding maximal neurite extension and higher densi-
ties inhibiting outgrowth. The adhesion site density that
yielded maximal outgrowth depended strongly on adhe-
sion site affinity in both two and three dimensions, with
lower densities of the higher affinity ligand being re-
quired (0.8–1.7 mol/mol for the linear peptide versus 0.2
mol/mol for the cyclic peptide yielding maximum neu-
rite outgrowth rates in three-dimensional cultures).
Cell adhesion and migration in two and three dimensions
play important roles in a host of physiological phenomena,
including neurite extension (1), angiogenesis (2), and immune
responses (3). The adhesion of cells within their environment is
controlled primarily by the binding of cell surface receptors to
short, exposed protein domains in the extracellular matrix. An
important receptor family involved in adhesion and migration
is the integrins, a class of heterodimeric receptors that interact
with both extracellular matrix and cell-surface ligands (4, 5).
Each unique dimeric receptor binds to a particular subset of
ligands, which can often be mimicked with immobilized short
peptides (6). One such short peptide that binds to integrins and
influences subsequent cell adhesion and migration is RGD, a
motif present in many proteins, including fibronectin, laminin,
collagen, and fibrinogen (7). This sequence has been shown to
be recognized by a5b1, avb3 (8), and several other integrin
heterodimer pairs.
Adhesion and migration upon a surface are distinct pro-
cesses that depend on related molecular mechanisms. Cell ad-
hesion involves the dynamic interaction between cell surface
receptors and adhesion ligands on the supporting matrix (9,
10), with the strength of this attachment being related to the
concentration of cell-surface receptors, the concentration of
ligands available, and the specific binding affinity of the recep-
tor ligands and pairs (11). Migration of cells upon a material is
an analogous phenomenon, with the rate of cell migration
depending on both ligand density and binding affinity as well
as the density of corresponding cell surface receptors. As cells
move within their environment, they must constantly detach at
the trailing edge and reattach at the leading edge to nearby
ligands (12, 13). The corresponding rate of cell migration upon
a surface depends on the simultaneous detachment and attach-
ment to nearby ligands, causing extreme ligand densities (both
high and low) to inhibit one of these two processes and subse-
quently limit cell migration rates. The outgrowth of neurites is
analogous to cell migration (14), with receptor cluster morphol-
ogy (15) and receptor dynamics at the growth cone (16) control-
ling the process.
Cell migration and neurite extension within a three-dimen-
sional matrix involves a more complex balance of cellular ac-
tivity than migration upon a two-dimensional surface, with
cell-associated proteolysis playing a key role in three-dimen-
sional migration. When cells are present inside a fibrin matrix
for example, the porosity of the fibrous network is significantly
smaller than the average cell and even neurite size. Therefore,
in order for cells or neurites to migrate within fibrin, it is
necessary that the surrounding matrix be remodeled, and this
is accomplished through the action of the protease plasmin
(17–19). While adhesion signals still play an important role in
three-dimensional migration, the dependence also on proteoly-
sis complicates a one-to-one correlation between two- and
three-dimensional cell migration.
The focus of this work was neurite migration within a fibrin
matrix with controlled adhesive characteristics. Through the
action of the transglutaminase, factor XIIIa, bi-domain pep-
tides were incorporated within a three-dimensional fibrin ma-
trix at precise and predetermined concentrations (20). A bi-
phasic response was observed in both two- and three-
dimensional neurite outgrowth, with intermediate RGD
adhesion site densities leading to fastest outgrowth. Outgrowth
rates depended strongly on binding affinity with a lower num-
ber of higher affinity binding sites leading to a similar response
as a higher number of lower affinity ligands.
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EXPERIMENTAL PROCEDURES
Peptides and Proteins—dLNQEQVSPLRGD-NH2 and dLNQEQVS-
PLRDG-NH2 (d 5 dansyl; for clarity, the factor XIIIa substrate domain
(21) is shown in italics) were synthesized on solid resin using an auto-
mated peptide synthesizer (9050 Pep Plus Synthesizer, Millipore,
Framingham, MA) with standard 9-fluorenylmethyloxycarbonyl chem-
istry (22). These peptides were labeled with a fluorescent probe by
including an a-dansylated leucine (Sigma, Buchs, Switzerland) at the
amino terminus of the peptide. Hydrophobic scavengers and cleaved
protecting groups were removed by precipitation of the peptide in cold
diethyl ether and dissolution in deionized water. After lyophilization,
these two peptides were redissolved in 0.03 M Tris-buffered saline
(TBS,1 pH 7.0) and analyzed using high performance liquid chromatog-
raphy (Waters, Milford, CT) on a size exclusion column with TBS, pH
7.0, as the running buffer. The cyclic peptide, NH2-LNQEQVSPD-
[CRGDNRC] (cyclic ring shown in brackets), was purchased from Gen-
emed (South San Francisco, CA) at greater than 85% purity.
Fibrinogen solutions were prepared by dissolving fibrinogen (Fluka,
Buchs, Switzerland) in deionized water at 8 mg/ml for 4 h. Dialysis
(Spectrum, 6000–8000 MWCO; Laguna Hills, CA) versus 400 volumes
of TBS, pH 7.4, for 24 h was used to exchange salts present in the
protein solution. The resulting solution was then sterilized by filtering
through a 0.22-mm syringe filter. The final fibrinogen concentration was
determined by measuring the absorbance of the protein solution at 280
nm (23). TBS solutions at pH 7.0 that were made with either 50 mM
Ca21 or without any Ca21 were sterilized by filtration though a 0.22-mm
filter. Fresh thrombin solutions were made by dissolving thrombin
(Sigma, Buchs, Switzerland) in TBS at pH 7.0 at a concentration of 20
units/ml.
Fibrin Formation—Fibrin gels were made in flat-bottomed 24-well
culture plates by mixing the four components such that final concen-
trations obtained were 1) 3.6 mg/ml fibrinogen, 2) 2.5 mM Ca21, 3) 2
NIH units/ml of thrombin, and 4) various amounts of added peptide.
DRG Dissection—DRGs were dissected from 8-day-old White Leg-
horn chicken embryos (24). Ganglia were temporarily stored in modified
neurobasal medium, consisting of insulin (5 mg/ml), transferrin (100
mg/ml), progesterone (6.3 ng/ml), putrascine (16.11 mg/ml), selenite (5.2
ng/ml), fibronectin (5 mg/ml), L-glutamine (0.5 mM), L-glutamate (25
mM), murine mouse nerve growth factor (20 ng/ml), 0.2% bovine serum
albumin, and 1% antibiotic-antimycotic added to neurobasal medium
(Life Technologies, Inc.).
Competitive Inhibition of Three-dimensional Neurite Outgrowth—
DRGs were cultured within 400 ml of unmodified fibrin gels, with the
gels being polymerized in the presence of a DRG such that one ganglion
was embedded three-dimensionally within the fibrin gel during polym-
erization. After polymerization, 1 ml of modified medium was added to
the matrices. In three series of experiments, the medium added after
fibrin gel polymerization was further supplemented with either of the
RGD peptides or the control RDG peptide added as soluble competitive
inhibitors. In the first experiment, the linear RGD peptide was added to
the medium at concentrations of 0, 0.21, 0.42, and 1.05 mM. The pep-
tide-supplemented medium was changed at 3, 6, and 9 h after seeding,
and the migration of neurites at 24 h was quantified and normalized to
that observed when 0 mg/ml soluble peptide was added. A second series
of experiments was performed in which the cyclic RGD peptide was
added as a competitive soluble inhibitor at the concentrations of 0, 0.08,
0.16, or 0.40 mM. Finally, a third series of experiments was performed
with the linear RDG peptide, where the peptide was added to the
medium at concentrations of 0, 0.21, 0.42, and 1.05 mM. The washing
and analysis procedures were identical to those used with the linear
RGD peptide, with the peptide-supplemented medium changed at 3, 6,
and 9 h. Neurite outgrowth was measured as described below.
Two-dimensional Neurite Outgrowth—DRGs were cultured upon fi-
brin gels without added exogenous peptides (all values were normalized
to this level of neurite extension within native fibrin) or with cross-
linked dLNQEQVSPLRGD-NH2, dLNQEQVSPLRDG-NH2 or LN-
QEQVSPD[CRGDNRC]. 300-ml gels were synthesized with various
amounts of peptide and washed at 3, 6, 9, and 24 h after gelation with
TBS to remove noncross-linked peptide. The peptides employed were
cross-linked at different densities. The linear RGD and RDG were
incorporated separately in a series of final concentrations that corre-
sponded to 0.8, 1.7, 4.4, and 8.2 mol of peptide/mol of fibrinogen,
obtained by polymerization of fibrinogen in the presence of 55, 110, 220,
275, and 330 mM peptide (20). The cyclic RGD was incorporated at 0.2,
0.4, 4.4, and 8.2 mol of peptide/mol of fibrinogen, obtained by polymer-
ization of fibrinogen in the presence of 13.75, 27.5, 275, and 330 mM
peptide. DRGs were placed on the surface of the fibrin gel and allowed
to adhere for 2 h before medium was added, and then the ganglia were
cultured on the surface of the matrix for 24 h. The neuronal medium
used was further modified by the addition of 1 mg/ml aprotinin to
prevent the ganglia from detaching from the surface due to protease
activity (17). Neurite extension was measured at 24 h after seeding as
described below.
Three-dimensional Neurite Outgrowth—DRGs were cultured within
400-ml fibrin gels without added exogenous peptides (all values were
normalized to this level of neurite extension within native fibrin) or
with cross-linked dLNQEQVSPLRGD-NH2, dLNQEQVSPLRDG-NH2,
or LNQEQVSPD[CRGDNRC]. These gels were polymerized in the pres-
ence of a DRG such that one ganglion was embedded three-dimension-
ally within the fibrin gel during polymerization. All peptides were
incorporated separately in a series of final concentrations that corre-
sponded to 0.8, 1.7, 4.4, and 8.2 mol of peptide/mol of fibrinogen,
obtained by polymerization of fibrinogen in the presence of 55, 110, 220,
275, and 330 mM peptide (20). The cyclic peptide was cross-linked into
the gel at two additional concentrations of 0.2 and 0.4 mol of peptide/
mol of fibrinogen, obtained from the addition of 13.75 and 27.5 mM
peptide during polymerization. The fibrin gels with embedded ganglia
were cultured in 1 ml of modified neurobasal medium, and the medium
was changed at 3, 6, 9, and 24 h after seeding to wash out noncross-
linked peptide. Neurite outgrowth was measured at 24 and 48 h after
seeding as described below.
Imaging—Images of the entire DRG and the outgrowing neurites
were collected using phase contrast microscopy with a 3 4.0 objective
(Zeiss, Zurich, Switzerland). At each time point, the average neurite
length extending from each DRG was measured by digital image proc-
essing as the area-averaged distance between the edge of the corona of
extending neurites and the DRG body, measured as described in detail
elsewhere (17).
Confocal scanning laser microscopy of DRGs was performed at 24 h
with a 103/0.30 Plan Neofluor objective (Zeiss) using a MRC 600
confocal system (Bio-Rad, Glattbrugg, Switzerland). 200-ml fibrin gels
containing various amounts of linear or cyclic RGD peptide or linear
RDG peptide were polymerized with a DRG within the gel in the center
of a 35-mm Petri dish. The DRGs were cultured in 2 ml of neuronal
medium, which was replaced once at 6 h to remove free peptide. Sam-
ples were stained at 24 h, prior to imaging, by adding 2 ml of a 5 mg/ml
stock solution of fluorescein diacetate in acetone to 1 ml of TBS. Ap-
proximately 50 images were taken at 10-mm intervals, and a composite
image was assembled using Imaris (Bitplane, Zurich, Switzerland)
image processing software on an Indigo2 extreme Silicon Graphics
Workstation (Silicon Graphics, Mountain View, CA).
Statistics—The outgrowth for each individual ganglion was normal-
ized by the mean neurite outgrowth observed for ganglia simulta-
neously cultured in or on unmodified fibrin. Experiments were com-
pleted in triplicate and these normalized values were then averaged to
express the change in outgrowth in relation to outgrowth observed to
unmodified fibrin. Statistical analyses of these data were performed
using Statview 4.5 (Abacus, Berkeley, CA). Comparative analyses were
completed using analysis of variance with Fisher’s protective t test at a
95% confidence level. Mean values and standard errors of the mean are
shown.
Linear curve fits were calculated for the data on inhibition with
soluble peptides using Cricket Graph III (Computer Associates), which
employs a linear least squares regression method. The analysis was
limited to the linear domain of the inhibition curves and was used to
determine the relative binding affinities of the two RGD peptides
employed.
RESULTS
Competitive Inhibition of Three-dimensional Neurite Out-
growth—As a measure of the relative binding affinity of the two
RGD peptides employed, the effect of each peptide as a soluble
competitive inhibitor of three-dimensional neurite outgrowth
from day 8 chick DRGs within fibrin was studied. When the
linear peptide, dLNQEQVSPLRGD, was added to the culture
medium, after fibrin polymerization, as a competitive inhibitor
in a concentration series, neurite outgrowth decreased in a
dose-dependent manner (Fig. 1). At the highest concentration
tested, 1.05 mM, the peptide decreased neurite outgrowth by
25 6 7% at 24 h relative to the outgrowth within unmodified
1 The abbreviations used are: TBS, Tris-buffered saline; DRG, dorsal
root ganglia.
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fibrin in the absence of soluble peptide inhibitor (p , 0.05). The
cyclic peptide LNQEQVSPD[CRGDNRC] decreased neurite
outgrowth to a greater extent compared with the linear pep-
tide, e.g. by 46 6 6% at 24 h when 0.40 mM peptide was added
to the medium. Furthermore, at every concentration point, the
cyclic RGD peptide inhibited the growth of neurites to a greater
extent than did the linear RGD peptide (p , 0.05). Linear curve
fits were calculated for the two active RGD peptides, and it was
found that the slope for the curve fit for the cyclic RGD peptide
was 9.0 times steeper than that for the curve fit for the linear
RGD peptide. The control sequence, RDG, proved to have no
effect on three-dimensional neurite outgrowth over the entire
concentration range tested (p . 0.52).
Neurite Extension in Two Dimensions with Cross-linked
RGD Sites—Fibrin gels were modified by cross-linking various
concentrations of either the linear RGD peptide, the cyclic RGD
peptide or the linear control RDG peptide, and a bi-phasic
RGD-dependent effect on two-dimensional neurite outgrowth
was observed (Fig. 2). When linear RGD was incorporated over
the range of 0–8.2 mol of peptide/mol of fibrinogen, the cross-
linking of 1.7 mol of linear RGD/mol of fibrinogen proved to
provide the greatest enhancement of neurite outgrowth, in-
creasing the level of neurite outgrowth by 23 6 9% at 24 h (p ,
0.05). Neurite outgrowth decreased for each of the higher pep-
tide densities such that when 8.2 mol of linear RGD/mol of
fibrinogen was incorporated the level of neurite outgrowth
decreased by 16 6 6% of the level seen in unmodified fibrin
matrices (p , 0.05). The incorporation of the cyclic RGD pep-
tide over the same concentration range demonstrated a similar
bi-phasic effect on neurite outgrowth, with the maximal en-
hancement occurring at a lower cross-linked peptide density.
When 0.2 mol of cyclic RGD/mol of fibrinogen was incorporated,
the level of enhancement proved to be 26 6 7% compared with
unmodified fibrin. Once again, at each of the higher peptide
densities, the level of neurite outgrowth decreased such that at
8.2 mol of cyclic RGD/mol of fibrinogen, the level of neurite
outgrowth was reduced by 22 6 5% of the level observed in
unmodified fibrin. The control sequence, RDG, proved to not
have an effect on neurite outgrowth over the entire concentra-
tion range tested, with the level of outgrowth similar to that in
unmodified fibrin (p . 0.74).
Neurite Extension in Three Dimensions with Cross-linked
RGD Sites—Fibrin gels were modified by cross-linking various
concentrations of linear or cyclic RGD or linear RDG peptide
into the gel, and the resulting effect on three-dimensional neu-
rite outgrowth was measured at 24 and 48 h. A bi-phasic
response was observed, with the cross-linking of 1.7 mol of
linear RGD peptide/mol of fibrinogen enhancing the level of
neurite outgrowth by 23 6 7% at 24 and 14 6 5% at 48 h (p ,
0.05) (Fig. 3). The incorporation of 4.4 or 8.2 mol of linear RGD
peptide/mole fibrinogen decreased the level of neurite out-
growth, such that it was lower than the outgrowth observed
within both unmodified fibrin as well as the fibrin modified
with lower concentrations of cross-linked peptide (p , 0.05). At
the highest incorporated adhesion density of 8.2 mol/mol, the
level of neurite outgrowth was reduced by 21 6 5% at 24 and
13 6 4% at 48 h relative to outgrowth within unmodified fibrin.
The incorporation of the higher affinity-binding cyclic pep-
tide, LNQEQVSPD[CRGDNRC], into fibrin gels had a similar
bi-phasic effect on the outgrowth of neurites, with an overall
effect that was shifted to lower peptide densities relative to the
effect for the lower affinity linear RGD peptide. Incorporation
of 0.2 mol/mol of cyclic peptide enhanced the outgrowth of
neurites by 17 6 7% at 24 and 14 6 3% at 48 h compared with
outgrowth within unmodified fibrin (p , 0.05). Each of the
higher cross-linking concentrations tested resulted in a de-
crease in neurite outgrowth, such that at 0.8 mol/mol, out-
growth was reduced by 25 6 7% at 24 and 16 6 4% at 48 h, and
at 8.2 mol/mol, neurite outgrowth was reduced by 51 6 5% at
24 and 25 6 5% at 48 h relative to outgrowth within unmodified
fibrin (p , 0.05). Incorporation of the RDG peptide had no
FIG. 1. The effect of soluble cyclic () or linear (M) RGD pep-
tides and a linear (f) RDG control peptide on neurite outgrowth
within three-dimensional fibrin matrices. Peptide was added in
the culture medium as a soluble competitive inhibitor for endogenous
RGD in the fibrin matrix. Neurite outgrowth from day 8 DRGs was
measured and normalized to outgrowth in unmodified fibrin at 24-h
culture time (nonnormalized value for unmodified fibrin is 0.207 6
0.010 mm). Experiments were performed in triplicate with six DRGs
per replicate, and mean values and S.E. are shown; * denotes p , 0.05
compared with unmodified fibrin. At each concentration point, the
cyclic peptide statistically inhibited neurite outgrowth to a greater
extent than did the linear peptide, demonstrating that the cyclic RGD
is a higher affinity ligand than the linear RGD. The incorporation of the
inactive control, RDG, did not affect neurite outgrowth at any of the
concentrations tested. Curve fits were calculated for the two RGD
peptides and are shown in dashed lines over the concentrations points
used in this calculation. The ratio of the binding affinities for the cyclic
RGD to the linear RGD (the ratio of the slope of the two linear curve
fits) is 9.0.
FIG. 2. The effect of incorporated cyclic () or linear (M) RGD
peptides and a linear (f) RDG peptide on neurite outgrowth
upon two-dimensional fibrin matrices. Neurite outgrowth from day
8 DRGs was measured and normalized to outgrowth in unmodified
fibrin at 24 h culture time (nonnormalized value for unmodified fibrin
is 0.238 6 0.010 mm). Experiments were performed in triplicate with
six DRGs per replicate, and mean values and S.E. are shown; * denotes
p , 0.05 compared with unmodified fibrin. The correlation between
two-dimensional neurite outgrowth and RGD density showed a bi-
phasic effect, with moderate densities of exogenous peptide eliciting the
greatest neurite outgrowth. The incorporation of the inactive control
peptide, RDG, did not affect two-dimensional neurite outgrowth at any
of the concentrations tested.
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statistically significant effect on neurite outgrowth at either 24
or 48 h at any of the concentrations tested (p . 0.36).
The relative binding affinities of the cyclic and the linear
peptides were estimated from the results on competitive inhi-
bition in three-dimensional outgrowth experiments. The cyclic
peptide was estimated to bind 9.0 times more strongly. This
ratio was used to compare the results in outgrowth with im-
mobilized linear and cyclic peptides in terms of affinity, rather
than molar amounts of peptide, by dividing the abscissa for the
linear peptide by 9.0. The adjusted results are shown in Fig. 3.
The curves, when adjusted according to relative affinity are
highly coincident.
The difference in outgrowth induced from the ganglia in the
various samples was pronounced enough to be clearly observed.
As a demonstration, a representative sample from materials
that induced the greatest and the smallest neurite outgrowth
are shown in Fig. 4. Samples are shown for the linear peptide
where maximal outgrowth (C) and minimal outgrowth (E) were
achieved. An identical set are present for the cyclic peptide (D
and F, respectively) in addition to representative samples for
the two controls, unmodified fibrin (A) and RDG modified fibrin
(B).
DISCUSSION
The migration of cells within a three-dimensional matrix is
an important component of many cellular processes both in
vivo and in vitro. However, the lack of three-dimensional model
materials in which the biochemical characteristics can be
readily and reproducibly controlled prevents complete under-
standing of the relevant factors involved. Through the factor
XIIIa-mediated modification of fibrin matrices, we have devel-
oped a method by which the bioactive character of a degradable
matrix can be reproducibly manipulated (20). Using these mat-
rices, the influence that exogenous RGD sequences have on the
outgrowth of neurites within a three-dimensional environment
was studied, with the effect on neurite outgrowth shown to
exhibit a bi-phasic dependence on RGD concentration and bind-
ing affinity.
The relative binding affinities of the peptides employed were
characterized by competitive inhibition experiments in three-
dimensional culture. RGD is found endogenously in fibrin, at
an active concentration of 2 mol/mol of fibrinogen (25). The
addition of either of the RGD peptides as a soluble inhibitor
blocked the activity of these endogenous sequences, resulting
in a decrease in neurite outgrowth within the fibrin matrix. A
high concentration of the linear RGD peptide (1.05 mM) was
required to decrease the outgrowth of neurites. The addition of
the cyclic RGD peptide as a soluble competitive inhibitor
proved to be much more potent in slowing neurite outgrowth,
such that at each tested concentration, the cyclic peptide in-
hibited neurite outgrowth to a greater extent than did the
linear peptide. When the data were correlated to a linear curve
fit, it was shown that the curve fit for the cyclic peptide was 9.0
times steeper then that for the linear RGD, indicating that the
binding affinity in this system for the cyclic peptide is 9.0 times
greater than that for the linear RGD peptide. This greater
binding affinity for cyclic RGD peptides over linear RGD pep-
tides has been demonstrated previously (26), with the en-
hanced binding affinity due to the forced secondary structure
occurring from the ring (27). It has been shown that cyclic RGD
peptides adopt a conformation similar to the turn between
strands in a b sheet, forcing cyclic peptides to mimic a common
structural motif for native RGD sites (28).
Two-dimensional neurite outgrowth demonstrated a bi-pha-
sic dependence on RGD site density, consistent with the out-
growth of neurites being a form of cell migration. Much exper-
imental and modeling work has been completed showing that
the effect of adhesion site surface concentration on the motility
of cells, such as smooth muscle cells, displays a bi-phasic re-
sponse (12, 29). The extent of the bi-phasic response in two
dimensions depends on the adhesion site and receptor surface
concentrations and the degree to which cell surface receptors
are polarized toward the leading edge (11). Evidence suggests
that the migration of the neuronal growth cone, and therefore
the overall neurite outgrowth rate, represents a similar phe-
nomenon (16). By incorporating RGD into a fibrin matrix, it has
been demonstrated that the neurite outgrowth from chick
DRGs displays such a bi-phasic dependence on RGD density,
with a moderate peptide density eliciting the highest out-
growth rate. These results are thus consistent with the migra-
tion of neuronal growth cones, and therefore neurite out-
growth, being directly analogous to the migration of individual
cells.
RGD peptides cross-linked into fibrin gels demonstrated a
bi-phasic adhesive-like character in three-dimensions. The
FIG. 3. The effect of incorporated cyclic () or linear (M) RGD
peptides and a linear (f) RDG peptide at various concentra-
tions on neurite outgrowth within three-dimensional fibrin
matrices. Neurite outgrowth from day 8 DRGs was measured and
normalized to outgrowth in unmodified fibrin at 24 (A) and 48 h (B)
culture time (nonnormalized value for unmodified fibrin is 0.207 6
0.010 mm at 24 h and 0.746 6 0.027 mm at 48 h). Experiments were
performed in triplicate with six DRGs per replicate, and mean values
and S.E. are shown; * denotes p , 0.05 compared with unmodified
fibrin, and ‡ denotes points that are statistically identical. The corre-
lation between neurite outgrowth and cross-linked linear RGD peptide
showed a similar bi-phasic effect as seen in two-dimensional RGD-de-
pendent cellular migration. The incorporated cyclic RGD peptide
showed a similar effect, with the curve shifted consistently to lower
concentrations due to its higher binding affinity. The relative binding
affinity ratio calculated from the curve fits of the competitive soluble
inhibition experiment (Fig. 1) was used to normalize the linear RGD
data at both 24 and 48 h (). When the linear RGD data are normalized
in this manner, both the 24- and 48-h neurite outgrowth are very
similar to that observed with the cyclic RGD peptide. The incorporation
of the inactive peptide, RDG, did not affect neurite outgrowth at any of
the concentrations.
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striking similarity between the results in three-dimensional
and two-dimensional outgrowth experiments suggest that the
rate-controlling phenomena are similar between the two cases.
This is very interesting, because in two-dimensional cultures
proteolysis plays a minor role, whereas in the three-dimen-
sional cultures proteolysis is required for neurite outgrowth
(17). The similarity in results suggests that proteolysis of the
fibrin matrix is not the rate-controlling phenomenon, but
rather that adhesion and migration biomechanics control the
overall outgrowth rate. The results also suggest, although in-
directly, that the density of exogenous RGD sites did not influ-
ence neurite outgrowth rates primarily by modulating local
protease activity. If they had done so, then the site density-de-
pendent bi-phasic response that was observed in three-dimen-
sional outgrowth (where proteolysis is requisite) would not
have been observed in two-dimensional outgrowth (where pro-
teolysis is not requisite) (17).
A strong dependence of both two-dimensional and three-
dimensional neurite outgrowth upon adhesion site binding af-
finity was observed. The phenomena observed for the two RGD
peptides employed were similar in both form and extent, but
with the response curve being markedly shifted to lower con-
centrations for the higher affinity cyclic RGD peptide such that
a significantly lower incorporated density of cyclic RGD was
required to induce maximal neurite outgrowth. To better quan-
tify this phenomenon, the three-dimensional outgrowth was
presented for the two RGD peptides in terms of comparable
adhesive density rather than peptide density. This was accom-
plished by first calculating the relative binding affinities for the
two RGD peptides from the competitive inhibition study. This
ratio was calculated to be 9.0 and was then used to correlate
the effects of the two RGD sequences by dividing the incorpo-
rated density for the linear peptide by this relative binding
affinity ratio. When this was done, the RGD-dependent neurite
outgrowth for the adjusted linear RGD peptide (Fig. 3, ) was
strikingly similar to that for the cyclic RGD peptide (Fig. 3, ).
Therefore, it is very likely that the lower density of the higher
affinity cyclic peptide, which induced maximal neurite out-
growth represents a total adhesive character similar to the
higher density of the lower affinity linear peptide, which in-
duced maximal neurite outgrowth as well. This is further sup-
ported in that the levels of enhancement of neurite outgrowth
for these two formulations are of similar intensities. Within the
concentration series tested, both RGD peptides demonstrated a
similar adhesive-like character in three-dimensional migra-
tion, and this character corresponds directly to effects seen in
the two-dimensional studies.
It has been recently demonstrated that integrin number in
the growth cone is regulated by receptor occupancy. Neurons
were purified from embryonic chick DRGs and plated on sur-
faces coated with either a low or high concentration of the
extracellular matrix protein laminin or the extracellular ma-
trix protein fibronectin. When the amount of a laminin-specific
integrin receptor, a6b1, was analyzed, it was shown to have
increased in the presence of low concentrations of laminin and
decreased in the presence of high concentrations of laminin
relative to similar neurons plated on fibronectin coated sur-
faces (30). This compensatory mechanism is hypothesized to
enable the neurite to migrate over a very wide range of adhe-
sion site densities. This compensatory mechanism may be less
at play in the fibrin model employed, as a clear response of
outgrowth rate to the adhesive characteristics of the matrix
was observed. It also may be possible that this compensatory
effect is even less at play in three-dimensional outgrowth, since
high immobilized concentrations of the high affinity cyclic RGD
ligand inhibited neurite outgrowth much more extensively in
three-dimensional culture than in two-dimensional culture, ap-
proximately 2-fold more.
The addition of exogenous adhesion sites within a fibrin
matrix is sufficient for enhancing two- and three-dimensional
neurite outgrowth. The overall process of neurite outgrowth
involves the simultaneous coordination of many individual pro-
cesses, including binding to both adhesion and other bioactive
sites, polymerization of actin, formation of new membrane, and
FIG. 4. Images of DRGs cultured
within unmodified fibrin (A), fibrin
with 8 mol of RDG/mol of fibrinogen
(B), fibrin with 1.7 mol of linear RGD/
mol of fibrinogen (C), fibrin with 0.2
mol of cyclic RGD/mol of fibrinogen
(D), fibrin with 8 mol of linear RGD/
mol of fibrinogen (E), and fibrin with
8 mol of cyclic RGD/mol of fibrinogen
(F). Confocal scanning laser microscopy
of DRGs was performed using 10x magni-
fication with approximately 50 images
taken at 10-mm intervals shown as an
extended focus projection. The scale bar
represents 100 mm. The ganglia grown
within unmodified fibrin show a similar
level of outgrowth to that seen within
RDG-modified fibrin gels. This level is
less than that observed in ganglia grown
within fibrin with low levels of incorpo-
rated RGD peptides (C and D) but greater
than that observed in ganglia grown
within fibrin with high levels of incorpo-
rated RGD peptides (E and F).
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intracellular migration of proteins within the axon (31–33).
While each of these components are necessary for neurite mi-
gration, it is possible that modulating a single factor might not
be sufficient to increase the overall rate of neurite migration.
By cross-linking various concentrations of exogenous RGD pep-
tides within a fibrin matrix formed from physiological fibrino-
gen concentrations, materials have been developed whereby
the likely change is in the adhesive character of the material.
These materials were able to modestly increase the level of
neurite outgrowth, demonstrating that adhesion of the migrat-
ing neurite growth cone is a significant and rate controlling
factor, even if it constitutes only one part of a complicated
process.
The use of biomaterials for tissue regeneration, such as the
promotion of nerve healing, is a promising field of research. By
developing materials with specific adhesive characteristics, it
is possible to control and enhance the level of cell migration
within the material. This may lead to more effective forms of
therapy in many areas of tissue engineering, such as promoting
better integration at the tissue-biomaterial interface, promot-
ing cell infiltration, and controlling morphogenesis in tissue
regeneration.
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